Home・Elenco Azioni・ENANTA PHARMACEUTICALS INC

ENANTA PHARMACEUTICALS INC

Chiusa

SettoreSettore sanitario

13.25 3.27

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

12.53

Massimo

13.62

Metriche Chiave
By Trading Economics
Entrata	-1.2M -13M
Vendite	-1.5M 17M
EPS	-0.45
Margine di Profitto	-76.292
Dipendenti	120
EBITDA	-958K -8.6M

Raccomandazioni
By TipRanks
Raccomandazioni	Acquista
Previsioni per 12 mesi	+54.44% upside

Dividendi
By Acuity
Utili prossimi	7 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-52M 370M
Apertura precedente	9.98
Chiusura precedente	13.25

Notizie sul Sentiment di mercato

By Acuity

31%

69%

97 / 340 Classifica in Healthcare

ENANTA PHARMACEUTICALS INC Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

3 ago 2026, 19:23 UTC

Enanta Pharmaceuticals Inc shares are rising amid a broader market rally, supported by gains in major technology stocks and renewed investor confidence.

31 lug 2026, 20:06 UTC

Enanta Pharmaceuticals Inc's shares are lower today, continuing a downward trend amid rising U.S. Treasury yields and crude oil prices. No specific news was identified.

30 lug 2026, 19:45 UTC

Enanta Pharmaceuticals Inc. is advancing, supported by broader market gains. Earlier in the session, shares pulled back from a session high.

29 lug 2026, 18:26 UTC

Enanta Pharmaceuticals Inc is declining in Wednesday's session, marking the seventh consecutive day of lower prices. No specific news has been identified to explain the movement.

28 lug 2026, 20:06 UTC

Enanta Pharmaceuticals Inc is declining, marking five consecutive sessions lower. The stock peaked earlier but has since pulled back amid broader market pressures.

27 lug 2026, 18:36 UTC

Enanta Pharmaceuticals Inc is higher today, building on Friday's momentum amid broader market dynamics following a decline in oil prices.

24 lug 2026, 20:06 UTC

Enanta Pharmaceuticals Inc. shares are lower today, reversing from a recent trend of higher daily closes since Thursday's close.

21 lug 2026, 19:31 UTC

Enanta Pharmaceuticals is rising during Tuesday's session, reflecting broader market strength and positive sentiment from recent earnings reports by General Motors and Novartis.

20 lug 2026, 19:46 UTC

Enanta Pharmaceuticals Inc shares are lower today, continuing a decline since Friday's close. The stock has shown significant volatility during the session.

Confronto tra pari

Modifica del prezzo

ENANTA PHARMACEUTICALS INC Previsione

Obiettivo di Prezzo

By TipRanks

54.44% in crescita

Previsioni per 12 mesi

Media 20 USD 54.44%

Alto 20 USD

Basso 20 USD

Basato su 1 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per ENANTA PHARMACEUTICALS INC - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

1 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 1 che hanno fornito valutazioni azionarie a ENANTA PHARMACEUTICALS INC - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

97 / 340 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo ENANTA PHARMACEUTICALS INC

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.